

AD \_\_\_\_\_

Award Number: W81XWH-12-1-0617

TITLE: Non-Invasive Cell-Based Therapy for Traumatic Optic Neuropathy

PRINCIPAL INVESTIGATOR: Shaomei Wang

CONTRACTING ORGANIZATION: Cedars-Sinai Medical Center  
Los Angeles, CA 90048

REPORT DATE: June 2015

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

|   |                                 |  |  |
|---|---------------------------------|--|--|
| <b>REPORT DOCUMENTATION PAGE</b>  |                                 | <i>Form Approved</i><br><i>OMB No. 0704-0188</i>   |  |
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b> |                                 |  |  |
| <b>1. REPORT DATE:</b><br>June 2015   | <b>2. REPORT TYPE:</b><br>Final | <b>3. DATES COVERED :</b><br>27Sep2012 - 26Mar2015 |  |
| <b>4. TITLE AND SUBTITLE:</b><br><br>Non-Invasive Cell-Based Therapy for Traumatic Optic Neuropathy   |                                 | <b>5a. CONTRACT NUMBER:</b> W81XWH-12-1-0617       |  |
|   |                                 | <b>5b. GRANT NUMBER:</b>                           |  |
|   |                                 | <b>5c. PROGRAM ELEMENT NUMBER</b>                  |  |
| <b>6. AUTHOR (S)</b><br>Shaomei Wang<br><br><br>E-Mail: shaomei.wang@cshs.org   |                                 | <b>5d. PROJECT NUMBER</b>                          |  |
|   |                                 | <b>5e. TASK NUMBER</b>                             |  |
|   |                                 | <b>5f. WORK UNIT NUMBER</b>                        |  |
| <b>7. PERFORMING ORGANIZATION NAME (S) AND ADDRESS (ES)</b><br><br>Cedars-Sinai Medial Center<br>8700 Beverly Blvd. AHSP, 8fl<br>Los Angeles, CA 90048  |                                 | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>    |  |
| <b>9. SPONSORING / MONITORING AGENCY NAME (S) AND ADDRESS (ES)</b><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012  |                                 | <b>10. SPONSOR/MONITOR'S ACRONYM (S)</b>           |  |
|   |                                 | <b>11. SPONSOR/MONITOR'S REPORT NUMBER (S)</b>     |  |
| <b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Approved for Public Release; Distribution Unlimited   |                                 |  |  |
| <b>13. SUPPLEMENTARY NOTES</b>  |                                 |  |  |

#### 14. ABSTRACT

1. Traumatic optical neuropathy (TON) results from trauma to optic nerve by head and eye injuries to both military and civilian population such as accidents, and blast related combat trauma. TON leads to irreversible blindness and represent a major public health burden with both economical and social impacts. Unfortunately, treatment is still rather limited. A large body of evidence indicates that TON affects optic nerve and its target neurons in the central nervous system, which provide vital retrograde trophic support to optic nerve. We hypothesize that systemic administration of bone marrow derived mesenchymal stem cells (MSC) to treat traumatic optic neuropathy (TON) will preserve/repair optic nerve, stabilize the unstable environment due to trauma and promote RGC regeneration and outgrowth by promoting the release of paracrine and autocrine mediators; induced Schwann cells from MSC (M-Sch) will repair the damaged RGC by remyelinating and providing multiple trophic factors. Previous studies have shown that activation in retinoic acid (RA) signalling triggers neurite outgrowth in adult mice. Here we found that intravitreal injection of retinoid X receptor agonist SR11237 not only preserved RGCs, and promoted RGC axon outgrowth at both 8 days and 14 days after TON. We have used Long Evan (LE) rats as a model for TON, MSC were isolated from LE rats, M-Sch were induced from MSC. Our main findings: (a) Using our modified forceps, a reliable and reproducible TON model was created. (b) Rat MSC and M-Sch were reliable produced for experiments. (c) Systemic administration of MSCs significantly preserved retinal ganglion cell survival after TON. (d) Systemic administration of MSCs also promote limited RGC axons regeneration. (e) Intravitreal injection of retinoid X receptor agonist SR11237 also protect RGC survival after TON and promote RGC regeneration. (f) Systemic administration of MSCs induced up expression of trophic factors in the retina (CNTF, BDNF, bFGF). (g) Intravitreal injection of retinoid X receptor agonist SR11237 combined with systemic administration of MSCs promote RGC survival and axons regeneration after TON.

This study showed that systemic administration of MSC could significantly protect retinal ganglion cells after TON. Intravitreal injection of SR11237 protect RGCs after TON and promote RGC axon regeneration. We also showed that up-regulation of trophic factors in the retina after MSC injection into TON model, which is, at least in part the mechanism of MSCs in protecting RGCs after injury.

#### 15. SUBJECT TERMS

None Listed

#### 16. SECURITY CLASSIFICATION OF:

a. REPORT  
U

b. ABSTRACT  
U

c. THIS  
PAGE  
U

#### 17. LIMITATION OF ABSTRACT

UU

#### 18. NUMBER OF PAGES

20

#### 19a. NAME OF RESPONSIBLE PERSON USAMRMC

#### 19b. TELEPHONE NUMBER (include area code)

## Table of Contents

|                                   | <u>Page</u> |
|-----------------------------------|-------------|
| Introduction.....                 | 5           |
| Body.....                         | 5           |
| Key Research Accomplishments..... | 11          |
| Reportable Outcomes.....          | 11          |
| Conclusion.....                   | 11          |
| References.....                   | 12          |
| Appendices.....                   | 13          |




## INTRODUCTION

Traumatic optical neuropathy (TON) results from trauma to optic nerve by head and eye injuries to both military and civilian population such as accidents, and blast related combat trauma [1-3]. In a military report, 82% of severe eye injuries were caused by blast and blast fragmentation. TON leads to irreversible blindness and represent a major public health burden with both economical and social impacts. Unfortunately, treatment is still rather limited. Cytokine-mediated neuroprotection has been repeatedly demonstrated, and reliably reproduced, in multiple animal models with a range of optic nerve injury conditions [4-6] and block neuronal cell death in an excitotoxicity animal model [7-9]. A significant challenge to clinical implementation of this work is that cytokines are rapidly degraded by endogenous proteases. So the effect is short lasting. A direct and reliable approach to stem cell-mediated neuroprotection is a rational approach. A large body of evidence indicates that TON affects optic nerve and its target neurons in the central nervous system, which provide vital retrograde trophic support to optic nerve [10-12]. As an alternative approach, we propose a **non-invasive, systemic delivery of stem cells to optic nerve and related target neurons in the brain**. The systemic administration of stem cells offers substantial advantages over local delivery. These cells can exert therapeutic effects over the injured optic nerve and its targeted neurons in the brain, and multiple injections can be performed if needed. Others have successfully used the intravenous administration of MSC for treating stroke, cerebral ischemia, brain injury and myocardial infarction [13-15]. Based on the extensive experience with both MSC and M-Sch as therapies for regenerative and degenerative medicine, this study will determine whether it is realistic to transfer this treatment to the clinical setting.

## BODY



1. Animal models: Long Evan rats are used throughout the study. Traumatic axonal injury (TAI) model was first created with a 60-g Yasargil aneurysm clip (Aesculap AG &CO, Tutlingen, Germany, arrow in image A) according to published protocol (16). However, we found it is impossible to use the Yasargil aneurysm clip, since it cannot perform 'dissecting', which is critical for free blood vessels from optic nerve bundle. We made a special clip by modifying a fine forceps (see image B). A reliable TAI model is created by using this modified forceps.




2. Isolation rat bone marrow derived mesenchymal stem cells (MSC, see image A); induction of Schwann cells from MSC (M-Sch, see image B) and MSC were purified with BD IMagnet combine with FACS analysis.

Isolation MSC from Long Evans rats using our published protocols (17), Image A showed MSC at passage 0.


Induction of Schwann cells from MSC according to published protocol (18-19). Image B showed antibody against S100 staining of Schwann cells induced from MSC. Graph C showed FACS analysis after CD54/CD90 selection.



**C**




### 3. RGC axon regrowth after injection of SR11237 following TON




Immediately after ONC, retinoid X receptor agonist SR11237 (4µM) was injected vitreously. CTb (green) was injected 3 days before animal euthanization. Optic nerves were collected at 7 and 14 days after ONC and stained with growth-associated protein 43 (GAP-43, red), counterstained with DAPI (blue). These images show that ONC without treatment, there is hardly regeneration of RGC axons; while in SR11237 treated eyes; there is regrowth of RGC axons at 7 and 14 days after ONC.

### 4. Inner retinal changes after intravitreal injection of SR11237 following TON




TON also affects photoreceptors: one week after TON, photoreceptor outer segments were obviously reduced in length even after retinoid X receptor agonist treatment compared with wild type untreated control.




Retinal sections were stained with antibody against cone arrestin after injection of SR11237 following ONC. At one week, cone morphology is preserved compared with normal control; while in untreated retina, both inner and outer segments were further reduced in length. Further examination showed that RGC dendrites as revealed by  $\beta$ III-tubulin (green) are also preserved







Retinal sections from SR11237 treated after ONC showed that there is up-regulation of  $\beta 1$  integrin (red) in the inner nuclear and RGC layers compared with normal untreated control.

##### 5. Trophic factor expression after intravenous injection of MSCs following TON





Total RNA was extracted from retinas 7days after TON following intravenous injection of 2 millions of MSCs; control samples were from untreated and TON without intravenous injection of MSCs. We found the expression of CNFT and bFGF was significantly higher in retina receiving MSC treatment compared with controls.

## 6. Functional evaluation

**Electroretinogram (ERG)** measure full-field retinal potential from the cornea. Under scotopic conditions, a-wave is generated by photoreceptor phototransduction; b-wave is mainly generated by depolarization of ON-bipolar cells and Müller cells. The Scotopic threshold responses (STR) are created from the inner most retina, where the RGC bodies are located.

Our study showed that at one week after ONC without treatment, both a-and b-waves reduced compared with untreated wild type rats. Further study with measuring STR did not detect significantly difference between TAI and TAI followed by MSC treatment.

### **Luminance threshold recording (LTR) from the superior colliculus**

The functional state of the retina was evaluated by recording the multi-neuronal responses in multiple (16–18) microelectrode penetrations into the unilateral superior colliculus (SC) of anesthetized rats. At each recording site, the receptive field was located by presenting flashes of the light spot of 3° in diameter. Response luminance threshold was then measured and defined as a minimal luminance of the stimulating light spot eliciting criterion multi-unit response (of amplitude twice of the level of the background activity). This procedure results in a map of focal luminance thresholds over the whole visual field of the eye contralateral to the tested SC. Based on these recordings, the cumulative curve of the luminance thresholds across the retina was calculated, which showed the percent of retinal area (y-axis) where the visual thresholds were less than the values indicated at the x-axis. Our LTR showed that there was no signal recorded after optic nerve crush, indicating the integrity of retina is needed for luminance threshold recording. We did not perform LTR during the second year.

## **KEY RESEARCH ACCOMPLISHMENTS**

- Reliable create TAI rat model by using our modified forceps
- Reliable isolate rat MSC and induction of Schwann cells from MSC (M-Sch)
- Worked out a new protocol for MSC purification with BD IMagent combine FACS analysis
- Reliable anterogradely label retinal ganglion cells and axons by injecting CTB into vitreous cavity; prepare for retinal whole mount
- Reliable retrogradely label retinal ganglion cells by applying fluorogold onto the superior colliculus
- Worked out protocol for quantifying retinal ganglion cells on retinal whole mount preparation
- Intravenous administration of MSC protect retinal ganglion cells after TAI and promote axons regeneration
- Intravenous injection of retinoid x receptor agonist protects RGCs and promote RGC axon regrowth after TON
- Intravenous injection of retinoid x receptor agonist also preserve inner retina
- Trophic factors-bFGF, CNTF and BDNF were up-regulated after TON following intravenous injection of MSCs
- Applying M-Sch to optic nerve crush site preserve retinal ganglion cells after TAI
- Luminance threshold recordings from the superior colliculus failed to detect retinal

- activities after TAI.
- Optokinetic response provides non-invasive measurement for TAI model

## **REPORTABLE OUTCOMES:**

The research was presented at ARVO, 2014, Orlando, FL.

Data collect is finished, manuscript is in preparation.

- **CONCLUSION:** We have reliably created rat model for TAI; reliably isolated MSC and induction of Schwann cells. We have found that non-invasive administration of MSC can protect retinal ganglion cells after TAI and local administration Schwann cells derived from MSC also protect retina ganglion cells. Systemic administration of MSC promotes axon regeneration, however axon regrowth is rather limited. To evaluate retinal function after TAI and intervention, optokinetic response also provides valuable indication of retinal function; and luminance threshold recording for the superior colliculus fails to record any retinal activities after TAI. Intravenous injection of retinoid X receptor agonist protects RGC survival and promotes RGC axon regrowth after TON. Trophic factors bFGF, CNTF and BDNF were up-regulated after intravenous injection of MSCs following TON. Future study: long-term evaluation of retinal ganglion cell protection and axon regeneration after intervention; new regents that have approved to promote axon regeneration combine with systemic administration of MSCs.

## **Future study**

Current study showed that intravenous injection of MSCs can protect RGCs and preserve retinal integrity after optic nerve crush in rat model. Intravitreal injection of retinoid X receptor agonist promotes RGC survival and RGC axon regrowth after optic nerve crush. However, the RGC axon regrowth is rather limited. Future study will use optic nerve injury model that is mild (without optic nerve transection), such as trauma. The critical step to preserve vision after optic nerve injury is to protect RGCs from dying even for 1-2 weeks, which will provide a window for other therapeutic intervention. Combined therapies are needed to preserve RGCs and promote its axons regrowth after optic nerve injury at the same time.



## REFERENCES

1. Steinsapir, K.D. and R.A. Goldberg, *Traumatic optic neuropathy*. Surv Ophthalmol, 1994. **38**(6): p. 487-518.
2. Steinsapir, K.D. and R.A. Goldberg, *Traumatic optic neuropathy: an evolving understanding*. Am J Ophthalmol, 2011. **151**(6): p. 928-933 e2.
3. Sarkies, N., *Traumatic optic neuropathy*. Eye (Lond), 2004. **18**(11): p. 1122-5.
4. Castillo, B., Jr., et al., *Retinal ganglion cell survival is promoted by genetically modified astrocytes designed to secrete brain-derived neurotrophic factor (BDNF)*. Brain Res, 1994. **647**(1): p. 30-6.
5. Klocker, N., et al., *In vivo neurotrophic effects of GDNF on axotomized retinal ganglion cells*. Neuroreport, 1997. **8**(16): p. 3439-42.
6. Mey, J. and S. Thanos, *Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo*. Brain Res, 1993. **602**(2): p. 304-17.
7. Kido, N., et al., *Neuroprotective effects of brain-derived neurotrophic factor in eyes with NMDA-induced neuronal death*. Brain Res, 2000. **884**(1--2): p. 59-67.
8. Kurokawa, T., et al., *BDNF diminishes caspase-2 but not c-Jun immunoreactivity of neurons in retinal ganglion cell layer after transient ischemia*. Invest Ophthalmol Vis Sci, 1999. **40**(12): p. 3006-11.
9. Unoki, K. and M.M. LaVail, *Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic fibroblast growth factor*. Invest Ophthalmol Vis Sci, 1994. **35**(3): p. 907-15.
10. Yip, H.K. and K.F. So, *Axonal regeneration of retinal ganglion cells: effect of trophic factors*. Prog Retin Eye Res, 2000. **19**(5): p. 559-75.
11. Isenmann, S., et al., *Short communication: protection of axotomized retinal ganglion cells by adenovirally delivered BDNF in vivo*. Eur J Neurosci, 1998. **10**(8): p. 2751-6.
12. Chen, H. and A.J. Weber, *BDNF enhances retinal ganglion cell survival in cats with optic nerve damage*. Invest Ophthalmol Vis Sci, 2001. **42**(5): p. 966-74.
13. Nagaya, N., et al., *Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis*. Am J Physiol Heart Circ Physiol, 2004. **287**(6): p. H2670-6.

14. Savitz, S.I., et al., *Intravenous autologous bone marrow mononuclear cells for ischemic stroke*. Ann Neurol, 2011. **70**(1): p. 59-69.
15. Chen, J., et al., *Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats*. Circ Res, 2003. **92**(6): p. 692-9.
16. Kawaguchi, I., et al., *In vivo imaging and quantitative evaluation of the rat retinal nerve fiber layer using scanning laser ophthalmoscopy*. Invest Ophthalmol Vis Sci, 2006. **47**(7): p. 2911-6.
17. Wang, S., et al., *Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology*. PLoS One, 2010. **5**(2): p. e9200.
18. Dezawa, M., et al., *Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation*. J Clin Invest, 2004. **113**(12): p. 1701-10.
19. Park, H.W., et al., *Human mesenchymal stem cell-derived Schwann cell-like cells exhibit neurotrophic effects, via distinct growth factor production, in a model of spinal cord injury*. Glia, 2010. **58**(9): p. 1118-32.
20. Hassani Z, O'Reilly J, Pearse Y, Stroemer P, Tang E, Sinden J, Price J, Thuret S. Human neural progenitor cell engraftment increases neurogenesis and microglial recruitment in the brain of rats with stroke. PLoS One. 2012;7(11):e50444.

**APPENDICES: PI's biosketch**

---

Principal investigator (Wang, Shaomei)

---

**BIOGRAPHICAL SKETCH**

|  |                                       |         |                     |
|--|---------------------------------------|---------|---------------------|
| NAME<br>Shaomei Wang   | POSITION TITLE<br>Associate Professor |         |                     |
| eRA COMMONS USER NAME<br>Wangsha   |                                       |         |                     |
| EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education,</i> |                                       |         |                     |
| INSTITUTION AND LOCATION   | DEGREE                                | YEAR(s) | FIELD OF STUDY      |
| Jinzhou Medical College, PR China  | B.M. (M.D)                            | 1984    | Medicine            |
| Chinese Medical University, PR China   | Masters                               | 1987    | Neuroscience        |
| University of Sheffield, UK  | Ph.D.                                 | 1997    | Visual neuroscience |
| Institute of Ophthalmology, UCL,<br>London   | Post-doc                              | 2001    | Cell-based therapy  |

## **A. Personal Statement**

Our laboratory has a long history of applying cell-based therapy for retinal degeneration. We have explored the efficacy of a range of different cell types (i) cells to replace defective retinal pigment epithelial (RPE) cells such as human embryonic stem cell derived –RPE cells, (ii) cells that appear to function by releasing growth factors such as peripheral nerve ensheathing cells (Schwann cells) or cells genetically modified to release growth factors and (iv) cells with multiple functions such as stem cells and progenitors. Our studies have provided the pre clinical data for three prominent first in man human clinical trials for retinal degeneration using either human embryonic stem cells (Advanced Cellular Therapeutics) or adult mesenchymal stem cells (Johnson and Johnson) or central nervous system derived neural stem cells (StemCell inc). Recently, my laboratory has pioneered a new approach to treatment involving systemic administration of mesenchymal stem cells and shown extensive morphological and functional preservation in rodent models of retinal disease. I was recruited to the Cedars-Sinai Regenerative Medicine Institute where we are collaborating with the director, Dr Clive Svendsen who has a long history of using stem cells to model and treat diseases of the CNS, Dr Alexander Ljubimov, director in eye program, and immunologists with an interest in transplantation. I will continue to work with our long-term collaborators Dr Gamm (U of Wisconsin) using retinal progenitors/stem cells to limit retinal degeneration. Our preclinical studies will be focused on the efficacy, long-term survival of donor cells, mechanism of action and immunological responses after cell-based therapy. The object of our translational research program is to treat retinal degeneration and optic nerve repair with cellular therapy.

## **B. Positions and Honors.**

### **Positions and Employment**

|              |   |
|--------------|---|
| 2012-present | Associate professor, Cedars-Sinai Regenerative Medicine Institute, LA, CA |
| 2006 - 2011  | Assistant Professor, Casey Eye Institute, OHSU, Portland, USA             |
| 2005- 2006   | Assistant Professor, Moran Eye Center, Utah, USA                          |
| 2001 - 2005  | Senior lab specialists, Moran Eye Center, Utah, USA                       |
| 1997 - 2001  | Post-doctoral fellow, Institute of Ophthalmology, UK                      |
| 1994 - 1997  | PhD student, University of Sheffield, UK.                                 |
| 1991 - 1993  | Visiting Scholar, University of Sheffield (supported by British Council). |
| 1987 – 1991  | Lecturer, JinZhou Medical College, PR China.                              |

### **Honors**

|           |   |
|-----------|---|
| 1984-1987 | Graduate studentship, Jinzhou Medical college, PR China   |
| 1991-92   | British Council and Chinese government award (visiting scholar to University of Sheffield, UK)    |
| 1992      | Overseas Research scholarship   |
| 2004      | Permanent US residency awarded in the US National Interest on the basis of outstanding researcher |
| 2010      | Paper was selected as Paper of the Month (March) at OHSU med school.                              |

2014      First prize Faculty elevator pitch at Regenerative Medicine Institute retreat

### **Other Experience and Professional Memberships**

Member of ARVO's Global Presence Pillar Steering committee  
Association for Research in Vision and Ophthalmology  
Society for Neuroscience  
Editorial member of Transplantation & technology and research  
Editorial member of International Journal of Ophthalmology  
Investigative Ophthalmology and Visual Science  
Experimental Eye Research  
Vision Research  
Current Eye Research  
Expert Reviews  
Stem cells international  
Plus ONE

### **B. Selected peer-reviewed publications**

Kwan A, Wang S, Lund RD. (1999) Reconstruction of photoreceptor layer in rodent model. *Exp Neurol* 159 (1): 21-33.

Coffey PJ, Girman SV, Wang S, Keegan DJ, Adamson P, Greenwood J, Lund RD. (2002) Long-term preservation of cortically mediated visual function in dystrophic RCS rats by transplantation of immortalised retinal pigment epithelial cells. *Nature Neuroscience*. 5:53-56.

Gamm DM, Wang S, Lu B, Girman S, Holmes T, Bischoff N, Shearer RL, Sauve Y, Capowski E, Svendsen CN, Lund RD. Protection of visual functions by human neural progenitors in a rat model of retinal disease. *PLoS ONE*. 2007 Mar 28;2:e338.

Wang S, Girman S, Lu B, Bischoff N, Holmes T, Shearer R, Wright L, Svendsen CV, Gamm DM, R Lund. Long Term Vision Rescue by Human Neural Progenitors in Rat Model of Photoreceptor Degeneration. *Invest Ophthalmol Vis Sci*. 2008 July; 49 (7): 3201-6.

Francis\* PJ, Wang\* S, Zhang Y, Brown A, Hwang T, McFarland T, Jeffrey, B.G, Lu B, Wright, L, Appukuttan B, Wilson, D.J, Stout, J.T, Neuringer M, Gamm\* DM, Lund\* RD. subretinal Transplantation of forebrain Progenitor Cells in Non-human Primates: Survival and Intact Retinal function. *Invest Ophthalmol Vis Sci*. 2009;50 (7): 3425-31.

Bin Lu\*, Christopher Malcuit\*, Shaomei Wang\*, Sergej Girman, Peter Francis, Linda Lemieux, Robert Lanza, Raymond Lund. Long-term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular Degeneration. *Stem Cells*. 2009;27 (9): 2126-35.

Lu B, Wang S, Francis PJ, Li T, Gamm DM, Capowski EE and RD Lund. Cell Transplantation to Arrest Early Changes in an USH 2A Animal Model. *Invest Ophthalmol Vis Sci*. 2009 Dec.3 (ePub).

Wang S\*, Lu B, Girman S, Duan J, McFarland T, Zhang QS, Grompe M, Adamus G, Appukuttan B and R Lund. Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. PLoS ONE 5(2):e9200.

Trevor J. McGill, Benjamin Cottam, Bin Lu, Shaomei Wang, Sergej. Girman, Alexandra Capela, Stephen L. Huhn, Ray D. Lund. Transplantation of human central nervous system stem cells: Neuroprotection in retinal degeneration. Euro J Neurosci 2012;35: 468-77.

Adamus Grazyna, Wang Shaomei, Kyger Madision, Worley Aneta, Lu Bin and Burrows Greg. Systemic immunotherapy delays photoreceptor cell loss and prevents vascular pathology in RCS rats. Molecular vision. 2012.

Jonathan G. Swoboda, Jimmy Elliott, Vishal Deshmukh, Lorenzo de Lichtervelde, Weijun Shen, Matthew S. Tremblay, Charles Y. Cho, Bin Lu, Sergej Girman, Shaomei Wang, Peter G. Schultz. Small molecule mediated proliferation of primary retinal pigment epithelial cells. ACS Chem Biol. 2013, May8

Nicolás Cuenca<sup>1</sup>, Laura Fernández-Sánchez<sup>1</sup>, Trevor J. McGill<sup>2</sup>, Bin Lu<sup>3</sup>, Shaomei Wang<sup>3</sup>, Raymond Lund<sup>4</sup>, Stephen Huhn<sup>5</sup>, Alexandra Capela. Phagocytosis of photoreceptor outer segments by transplanted human neural stem cells as a neuroprotective mechanism in retinal degeneration. Invest Ophthalmol Vis Sci. 2013, Sep 17.

Bin Lu, Catherine W Morgans, Sergey Girman, Raymond Lund and Shaomei Wang. Retinal Morphological and Functional Changes in an Animal Model of Retinitis Pigmentosa. Vis Neurosci, 2013: 1-13.

Bin Lu, Catherine W. Morgans, Sergey Girman, Jing Luo, Jiagang Zhao, Hongjun Du, SiokLam Lim, Sheng Ding, Clive Svendsen, Kang Zhang and Shaomei Wang. Neural Stem Cells Derived by Small Molecules Preserve Vision. Transl Vis Sci Technol. 2013: 2.

Tsai YC, Lu B, Girman S, Ross-Cisneros FN, Sadun AA, Svendsen CN, Ljubimov AV, Cohen RM, Wang S. Ocular changes in TgF344-AD rat model of Alzheimer's Disease. Invest Ophthalmol Vis Sci. 2014: 55: 1523-534.

Lu B, Lin Y, Tsai Y, Girman S, Adamus G, Jones MK, Shelley B, Svendsen CN, Wang S. A Subsequent Human Neural Progenitor Transplant into the Degenerate Retina Does Not Compromise Initial Graft Survival or Therapeutic Efficacy. Trans Vis Sci Technol 2015;4:1.

Yuchun Tsai<sup>†</sup>, Bin Lu<sup>†</sup>, Benjamin Bakondi, Sergey Girman, Anais Sahabian, Dhruv Sareen, Clive N. Svendsen, Shaomei Wang. Human iPSC-derived neural progenitors preserve vision in an AMD-like model. Stem Cells, 2015, April

## Abstracts

Sergej Girman and Shaomei Wang. Earliest manifestation of MERTK mutation: Abnormal ERG recovery after brief exposure to moderate light in very young RCS rats 2013, ARVO, D0290.

Bin Lu; YuChun Tsai; Grazyna Adamus; Sergey Girman; Lin Shen; David M. Gamm; Catherine W. Morgans; Brandon Shelley; Clive Svendsen; Shaomei Wang. Effect of Repeated Delivery of Neural Progenitors on Vision Preservation in RCS Rats 2013, ARVO, A0030.

Shaomei Wang; YuChun Tsai; Sergey Girman; Lin Shen; Catherine W. Morgans; Grazyna Adamus; Weidong Xiong; Vaithi Arumugaswami; Clive Svendsen; Bin Lu. Manipulating MSC Homing To Enhance Its Efficacy in Preserving Vision 2013, ARVO, B0194.

YuChun Tsai; Bin Lu; Sergey Girman; Clive Svendsen; Robert M. Cohen; Shaomei Wang. Ocular changes in a rat model of Alzheimer's Disease 2013, ARVO, D0232.

Jing Yang, Geoffrey P. Lewis; Bin Lu; Nikolay Turovets; Gabriel Luna; Sergey Girman; Gerhard Bauer; Steven K. Fisher; Shaomei Wang; Henry J. Klassen. Translational development of human retinal progenitor cells for treatment of retinitis pigmentosa 2013, ARVO, A0106.

Benjamin Bakondi; YuChun Tsai; Bin Lu; Sergey Girman; Lin Shen; Melissa K. Jones; Shaomei Wang. Is Mesenchymal Stem Cell Homing To The Injured Retina Required For Visual Preservation In The RCS Rat? 2014, ARVO, A0133.

YuChun Tsai; Bin Lu; Sergey Girman; Benjamin Bakondi; Melissa K. Jones; Anais Sahabian; Dhruv Sareen; Clive Svendsen; Shaomei Wang. Human iPSC-derived neural progenitor cells preserve vision in a rat retinal degeneration model. 2014, ARVO, D0037.

Melissa K. Jones; Bin Lu; Sergey Girman; YuChun Tsai; Benjamin Bakondi; Brandon Shelley; Alexander V. Ljubimov; Clive Svendsen; Shaomei Wang. In vivo study of neural progenitors after injection into a retinal degeneration rodent model. 2014, ARVO, C0172.

Shaomei Wang; YuChun Tsai; Benjamin Bakondi; Sergey Girman; Lin Shen; Bin Lu. Systemic administration of MSCs preserves RGC survival after optic nerve crush. 2014. ARVO, B0139.

### **C. Current Grant Support**

1R01EY020488 Wang (PI)  
09/01/2011-08/31/2016

NIH/NEI

Development of non-invasive cell-based therapy for retinal degeneration and associated vascular pathology.

The overall objective of this research proposal is to preserve vision and limit vascular pathology using non-invasive MSC therapy in rodent models for retinal degeneration. The MSCs have been widely used in both regenerative and degenerative medicine. The proposed research will be critical in determining whether systemic administration of MSCs offers a realistic likelihood of translation to the clinic for the treatment of retinal degeneration and ocular vascular pathology.

Role: PI

CS-RMI (start-up fund) Wang (PI)  
06/01/2011-05/31/2015

Applying stem cell therapy for retinal degenerative disease

Department of Defense Wang (PI) 09/01/12-08/31/14  
Non-invasive cell based therapy for traumatic optic neuropathy

Janssen Research & development, LLC Wang (PI) 08/01/13-07/31/15  
Preclinical research with umbilical derived stem cell therapy for RCS rodent model for retinal degeneration.

The Simon and Beatrice Apple Stem cell fund Wang (PI) 04/01/2014-03/21/2016  
Develop personalized stem cells for treating AMD

Poster presented at ARVO meeting at Orlando, May 2014.

Poster board Number: 2440 - B0139



## Systemic Administration of MSCs Preserves RGC Survival after Optic Nerve Crush

Wang S, Lin Y, Tsai Y, Bakondi B, Girmán S, Shen L, Svendsen C and B Lu  
Regenerative Medicine Institute, Department of Biomedical Science, Cedars-Sinai Medical Center, CA 90048



**Abstract**  
**Purpose:** Traumatic optic neuropathy (TON) is an acute injury of the optic nerve with disruption of visual function. TON results from trauma to optic nerve by head and eye injuries to both military and civilian population such as accidents, recreation and blast related combat trauma. TON leads to irreversible blindness and represent a major public health burden with both economical and social impacts. Unfortunately, treatment is still rather limited. A large body of evidence indicates that TON affects optic nerve and its target neurons in the central nervous system, which provide vital retrograde trophic support to optic nerve. Here we used systemic administration of bone marrow derived mesenchymal stem cells (MSC) to treat TON in a well-established rat model-optic nerve crush (ONC).  
**Methods:** Long Evans rats, both sex at 6-8 weeks old were used for creating ONC model (one side) with customized forceps. On the next day, 2 millions of MSC-derived from Long Evans rats were injected via tail vein. Visual function was tested by optokinetic response, luminance threshold recording from the superior colliculus and electroretinograph at 8 and 14 days after ONC. Survival retinal ganglion cells (RGCs) were quantified by applying fluorogold to the superior colliculus and antibody-Bn3 staining on retinal whole-mount preparation. Optic nerve axons were examined by injecting CTB intravitreally and antibody-RT97 staining. Stereology was used to count the number of RGC survival.

**Results:** There was about 60% RGC survived in animals with intravenous injection of MSC after ONC, compared with 40% RGC survival in control animals (no treatment after ONC). This difference is significant ( $p < 0.05$ ). The visual acuity was also preserved in MSC treated animals compared with control. Luminance threshold recordings revealed there was no signal detected after ONC, indicating the integrity of retina is required for luminance threshold recording. On all the MSC treated animals, there were some RGC axons regeneration, force manipulations to enhance axons grow is needed.

**Conclusions:** Systemic administration of allogeneic MSC promotes RGC survival and enhances RGC axon regeneration after optic nerve crush. Long-term study using this approach to preserve both RGC and its axons is under investigation.

**Introduction**  
Traumatic optic neuropathy (TON) is an acute injury of the optic nerve with disruption of visual function. TON results from trauma to optic nerve by head and eye injuries to both military and civilian population such as accidents, recreation and blast related combat trauma. TON leads to irreversible blindness and represent a major public health burden with both economical and social impacts. Unfortunately, treatment is still rather limited. A large body of evidence indicates that TON affects optic nerve and its target neurons in the central nervous system, which provide vital retrograde trophic support to optic nerve. Here we used systemic administration of bone marrow derived mesenchymal stem cells (MSC) to treat TON in a well-established rat model-optic nerve crush (ONC).  
**Methods:** Long Evans rats, both sex at 6-8 weeks old were used for creating ONC model (one side) with customized forceps. On the next day, 2 millions of MSC-derived from Long Evans rats were injected via tail vein. Visual function was tested by optokinetic response, luminance threshold recording from the superior colliculus and electroretinograph at 8 and 14 days after ONC. Survival retinal ganglion cells (RGCs) were quantified by applying fluorogold to the superior colliculus and antibody-Bn3 staining on retinal whole-mount preparation. Optic nerve axons were examined by injecting CTB intravitreally and antibody-RT97 staining. Stereology was used to count the number of RGC survival.


### Material and Methods

**MSCs** were isolated from bone marrow of Long Evans rats (6-8 weeks old) according to the method described (Wang et al. 2010). MSCs were purified by applying fluorogold to the superior colliculus and antibody-Bn3 staining on retinal whole-mount preparation. Optic nerve axons were examined by injecting CTB intravitreally and antibody-RT97 staining. Stereology was used to count the number of RGC survival.



**Optic nerve crush (ONC)** Long Evans (LE) rats at 6-8 weeks were used to create ONC model with customized forceps. On the next day, 2 millions of MSC-derived from Long Evans rats were injected via tail vein. Visual function was tested by optokinetic response, luminance threshold recording from the superior colliculus and electroretinograph at 8 and 14 days after ONC. Survival retinal ganglion cells (RGCs) were quantified by applying fluorogold to the superior colliculus and antibody-Bn3 staining on retinal whole-mount preparation. Optic nerve axons were examined by injecting CTB intravitreally and antibody-RT97 staining. Stereology was used to count the number of RGC survival.

**Quantification of survival and outgrowth of RGC.** Retrograde tracer-fluorogold was applied to the superior colliculus 7 days before sacrificed animals. Retinal whole mount will be prepared to quantify RGC survival with our published protocol. Anterograde tracer: CTB was injected into vitreous cavity to examine RGC regeneration histologically.


**Visual function** was tested by optokinetic response (OKR) and luminance threshold recording (LTR) with our published protocol. **Retinal whole mount:** At the end of the experiment, retinal whole mount was prepared, antibody against Bn-3a was used to identify RGCs, montage images were taken. Stereology was used to count the number of RGCs using an Axiovert 35MOT Zeiss microscope with a x2.5 objective lens. A semi-automatic stereology system to trace the area of interest, and a 40x magnification to count RGCs. **Retinal sections** were examined for photoreceptors and inner retinal changes after ONC and treatments




MSC were isolated from Long Evans rats (6-weeks old) according to our published protocol (Wang et al. 2010). Passage 2-4 was used in this study. A: MSC at Passage 1. B: Induction of Schwann cells from MSC according to Demina et al. 2008. The image showing 5100 staining of Schwann cells induced from MSC.




D: 40x magnification image of the clip was used to create optic nerve crush (ONC) model. However, it turned out the clip was too big to be inserted into the optic nerve. E: Customized forceps were used to create optic nerve crush model reliably.




F: Retrograde labeling retinal ganglion cells by applying fluorogold to the superior colliculus. Here is the retinal whole mount image showing fluorogold labeled retinal ganglion cells and high power image of fluorogold labeled retinal ganglion cells. G: Optic Fractionator was used to count RGCs.



H: Optical Fractionator was used to count RGC number in retinal whole mount preparation from wild type, one week after optic nerve crush with intravenous injection of MSC or untreated as control. It showed that MSC treated eyes have significant RGC survival compared with untreated control. There was about 60% RGC survival compared to wild type in MSC treated eyes while in untreated eye, there was 30% RGC survival. I: Optokinetic response (OKR) revealed that there was no significant difference between MSC treated and untreated controls at one week after ONC. Other functional tests including ERG and luminance threshold recordings from the superior colliculus did not revealed any difference between treated and untreated controls (data not show).




Chondra toxin B (CTB) was injected into vitreous cavity after ONC 3 days before euthanization of animals to anterogradely label RGC axons. J: one week after ONC without treatment, there is limited optic nerve regeneration. K: one week after ONC with intravenous injection of 2 millions of MSCs, there are some optic nerve regeneration (dotted arrows).




L: Immediately after ONC, retinal X receptor against SR11237 (4μM) was injected intravitreally. CTB (green) was injected 3 days before animal euthanization. Optic nerves were collected at 7 and 14 days after ONC and stained with growth-associated protein 43 (GAP-43, red), counterstained with DAPI (blue). These images show that ONC without treatment, there is hardly regeneration of RGC axons (A-C), while in SR11237 treated eyes, there is regrowth of RGC axons at 7 (D-F) and 14 (G-I) days after ONC.

Abbreviations: CTB: Chondra toxin B; BSS: balanced salt solution; ERG: electroretinography; GAP-43: Growth-associated protein 43; INL: inner nuclear layer; MSC: mesenchymal stem cells; ONL: outer nuclear layer; OKR: optokinetic response; ONC: optic nerve crush; RGC: retinal ganglion cells; RPE: retinal pigment epithelium; SR11237: Retinal X receptor agonist; SDH: S-100 protein derived factor.



M-P: Retinal sections were stained with antibody against cone arrestin after injection of SR11237 following ONC. At one week, cone morphology is preserved compared with normal control while in untreated retina, both inner and outer segments were further reduced in length. Further examination showed that RGC dendrites as revealed by βIII-tubulin (green) are also preserved (Q&R).



**Results:**  
1. Intravenous injection of bone marrow derived mesenchymal stem cells (MSC) can protect retinal ganglion cells after optic nerve crush.  
2. Intravenous injection of MSC also promote limited regeneration of RGC axons following ONC.  
3. Retained X receptor agonist can protect RGC survival and promote RGC axon regeneration.  
4. Visual function was not improved with MSC treatment after ONC.  
5. ONC also affects morphology of photoreceptors.

**Further study:**  
1. Enhance RGC survival and promote RGC axon regeneration by combined treatment such as local injection of SR11237 and intravenous injection of MSC.  
2. To investigate the mechanism of action of MSC in protecting RGCs.  
3. Local delivery trophic factors by Schwann cells combined with systemic injection of MSC.  
4. Preserving photoreceptors and retinal integrity should be taken into consideration when applying therapy for optic nerve damage.

**Acknowledgements:** This project was supported by Department of Defense (W81XWH-12-1-0617), NIH (R01 EY020488-01), Foundation Fighting Blindness; Fund from Regenerative Medicine Institute at CSCM.

Commercial relationship disclosure: Non